Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    No additions or deletions were detected for the study page (NCT03957551) in the provided screenshots and text; the page content appears unchanged.
    Difference
    0.5%
    Check dated 2025-11-03T21:32:19.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    32 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    2%
    Check dated 2025-10-06T08:12:24.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.
    Difference
    0.1%
    Check dated 2025-09-29T04:48:34.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision bumped from v3.0.1 to v3.0.2; removed 'Back to Top'. No substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-14T23:10:42.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-07T19:49:17.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the early termination of a study on Cabozantinib and Pembrolizumab for advanced metastatic melanoma, with new results reporting dates and changes in study design details. Key metrics such as overall survival and progression-free survival definitions have been clarified and updated.
    Difference
    16%
    Check dated 2025-08-31T12:28:43.000Z thumbnail image

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.